...
首页> 外文期刊>Neurology. >Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3–4) Gliomas
【24h】

Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3–4) Gliomas

机译:Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3–4) Gliomas

获取原文
获取原文并翻译 | 示例
           

摘要

Posttreatment radiologic deterioration of an irradiated high-grade (WHO grade 3–4) glioma (HGG) may be the result of true progressive disease or treatment-induced effects (TIE). Differentiation between these entities is of great importance but remains a diagnostic challenge. This study assesses the diagnostic value of conventional MRI characteristics to differentiate progressive disease from TIE in HGGs. In this single-center, retrospective, consecutive cohort study, we included adults with a HGG who were treated with (chemo-)radiotherapy and subsequently developed a new or increasing contrast-enhancing lesion on conventional follow-up MRI. TIE and progressive disease were defined radiologically as stable/decreased for ≥6 weeks or Response Assessment in Neuro-Oncology progression and histologically as TIE without viable tumor or progressive disease. Two neuroradiologists assessed 21 preselected MRI characteristics of the progressive lesions. The statistical analysis included logistic regression to develop a full multivariable model, a diagnostic model with model reduction, and a Cohen kappa interrater reliability (IRR) coefficient. A total of 210 patients (median age 61 years, interquartile range 54–68, 189 male) with 284 lesions were included, of whom 141 (50%) had progressive disease. Median time to progressive disease was 2 (0.7–6.1) and to TIE 0.9 (0.7–3.5) months after radiotherapy. After multivariable modeling and model reduction, the following determinants prevailed: radiation dose (odds ratio [OR] 0.68, 95% CI 0.49–0.93), longer time to progression (TTP; OR 3.56, 95% CI 1.84–6.88), marginal enhancement (OR 2.04, 95% CI 1.09–3.83), soap bubble enhancement (OR 2.63, 95% CI 1.39–4.98), and isointense apparent diffusion coefficient (ADC) signal (OR 2.11, 95% CI 1.05–4.24). ORs >1 indicate higher odds of progressive disease. The Hosmer & Lemeshow test showed good calibration ( p = 0.947) and the area under the receiver operating characteristic curve was 0.722 (95% CI 0.66–0.78). In the glioblastoma subgroup, TTP, marginal enhancement, and ADC signal were significant. IRR analysis between neuroradiologists revealed moderate to near perfect agreement for the predictive items but poor agreement for others. Several characteristics from conventional MRI are significant predictors for the discrimination between progressive disease and TIE. However, IRR was variable. Conventional MRI characteristics from this study should be incorporated into a multimodal diagnostic model with advanced imaging techniques. This study provides Class II evidence that in patients with irradiated HGGs, radiation dose, longer TTP, marginal enhancement, soap bubble enhancement, and isointense ADC signal distinguish progressive disease from TIE.
机译:治疗后的放射恶化辐照高档神经胶质瘤(3 - 4年级)(HGG)可能是真正进步的结果疾病或treatment-induced效应(领带)。这些实体之间的分化重视但仍是诊断挑战。常规MRI特点的价值区分进步的疾病从领带HGGs。连续队列研究,我们包括成年人一个HGG治疗(化疗)放射治疗随后开发了一个新的或增加充当病变在传统后续磁共振成像。放射检查定义为稳定/下降≥6周或响应评估神经肿瘤学学会举办的领带没有进展和组织学检查可行的肿瘤或进步的疾病。神经放射21预选的MRI评估进步的病变特点。统计分析包括逻辑回归开发一个完整的多变量模型中,减少诊断模型与模型,科恩kappa评分者间信度(IRR)系数。61年,四分位范围54 - 68,189名男性)病变包括284,其中有141 (50%)有进步的疾病。进步的疾病是2(0.7 - -6.1)和领带0.9(0.7 - -3.5)个月后放疗。多变量建模和模型降阶,以下因素占了上风:辐射剂量[或](优势比为0.68,95%可信区间0.49 - -0.93),时间更长时间进程(TTP;1.84 - -6.88),边缘增强(或2.04,95%可信区间1.09 - -3.83),肥皂泡增强(或2.63、95%可信区间1.39 - -4.98),isointense表观扩散系数(ADC)信号(或2.11,95%可信区间1.05 - -4.24)。进步的疾病。显示良好的校准(p = 0.947)和该地区接受者操作特性曲线为0.722 (95% CI 0.66 - -0.78)。子群,TTP、边缘增强和ADC信号是重要的。神经放射显示中度到附近预测项目但完美的协议可怜的协议。从常规的MRI特征歧视的重要预测因子进步的疾病之间和领带。是变量。从这个研究应该被纳入多通道用先进的成像诊断模型技术。在辐照HGGs患者,辐射剂量,延长TTP,边缘增强,肥皂泡沫增强,isointense ADC的信号区分进行性疾病和领带。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号